Rocket Lab's Electron backlog tops 100 missions after largest commercial deal with Synspective

What happened

Rocket Lab announced that Synspective ordered 20 additional Electron launches, scheduled yearly from 2028 through 2031, marking the largest commercial Electron deal in the company's history. This brings Rocket Lab's total launch backlog to over 100 missions, a sharp increase from more than 70 in early May, reflecting strong repeat business from existing customers like Synspective. The deal underscores the reliability and cadence of the Electron small launch vehicle, which has already completed 95 launches overall and 16 in 2026, and provides multi-year revenue visibility for the launch services segment. However, while this strengthens Rocket Lab's core operating business, the company's stock remains primarily valued on the success of its medium-lift Neutron rocket, whose first launch is still gated by qualification milestones and pad delivery in Q4 2026. Moreover, the pending Iridium acquisition and recent equity dilution continue to weigh on per-share economics, suggesting that the new Electron backlog alone may not justify the current premium valuation.

Implication

Short-term, the news may provide a modest sentiment boost, but it does not address the key risks that underpin the cautious rating from the master report. The Electron backlog growth demonstrates strong execution and customer trust, which supports the company's long-term fundamentals and could cushion downside if Neutron faces delays. However, with the stock trading near $70, well above the attractive entry level of $55 identified in the master report, the risk-reward remains skewed to the downside for new positions. Investors should focus on whether Rocket Lab can deliver Neutron to the pad by Q4 2026 and secure named 2027 missions, as these are the primary catalysts that could unlock medium-lift revenue and re-rate the stock. Additionally, monitoring the Iridium transaction closure and any further equity issuance will be crucial, as additional dilution could further pressure per-share value despite operational strength.

Thesis delta

The new Electron backlog slightly strengthens the fundamental value of Rocket Lab's existing launch business, reinforcing the view that Electron is a solid, high-cadence operation. However, it does not alter the core thesis concerns: Neutron's first launch remains a critical, unresolved catalyst, and the Iridium acquisition continues to introduce dilution and financing risk. Therefore, the thesis remains a cautious 'Potential Sell' with the same valuation levels, as the stock is still priced for medium-lift success that has not yet been proven.